The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Open accessAbstract
BACKGROUND: In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels for periods of up to 16 months. We wanted to determine the durability of transgene expression, the vector dose-response relationship, and the level of persistent or late toxicity. METHODS: We evaluated the stability of transgene expression and long-term safety in 10 patients with severe hemophilia B: 6 patients who had been enrolled in an initial phase 1 dose-escalation trial, with 2 patients each receiving a low, intermediate, or high dose, and 4 additional patients who received the high dose (2×10(12) vector genomes per kilogram of body weight). The patients subsequently underwent extensive clinical and laboratory monitoring. RESULTS: A single intravenous infusion of vector in all 10 patients with severe hemophilia B resulted in a dose-dependent increase in circulating factor IX to a level that was 1 to 6% of the normal value over a median period of 3.2 years, with observation ongoing. In the high-dose group, a consistent increase in the factor IX level to a mean (±SD) of 5.1±1.7% was observed in all 6 patients, which resulted in a reduction of more than 90% in both bleeding episodes and the use of prophylactic factor IX concentrate. A transient increase in the mean alanine aminotransferase level to 86 IU per liter (range, 36 to 202) occurred between week 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (range, 2 to 35) after prednisolone treatment. CONCLUSIONS: In 10 patients with severe hemophilia B, the infusion of a single dose of AAV8 vector resulted in long-term therapeutic factor IX expression associated with clinical improvement. With a follow-up period of up to 3 years, no late toxic effects from the therapy were reported. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00979238.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further studies confirmed that the capsid-specific immune response is dose-dependent and administration of low vector doses of AAV are more likely to induce mild inflammation that is manageable by steroids [86–88].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [87]
In the citing paper
“The initial clinical studies of AAV-based gene transfer targeting liver correlated the AAV-specific cytotoxic T lymphocytes activation with transaminitis and loss of transgene expression”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“therefore studies of AAV immunogenicity focused mainly on the adaptive immune responses against AAV-transduced hepatocytes (38, 39).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“Moreover, a recent meta-analysis of clinical trials using hepatic AAV gene transfer concluded that vectors rich in CpG motifs results in failure to achieve sustained expression, owing to activation of capsid specific CD8+ T cells (19–22).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“Antibody formation against capsid was also not impacted by CpG depletion in clinical trials (19, 57).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“These studies however build evidence that short-course CCS alone is likely to be insufficient to inhibit formation of capsid-reactive T cells (13) and rAAV-mediated immune response with systemic high dosages.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
In the citing paper
“In the subsequent study using AAV8, administration of steroids was able to negate this response and maintain therapeutic FIX levels albeit a 50-70% decline from peak levels (13).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L. A., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Self-citationNathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball‐Cook, G., McIntosh, J., Boon‐Spijker, M., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 419
Self-citationNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2006) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Let-7 suppresses liver fibrosis by inhibiting hepatocyte apoptosis and TGF-β production
Song, J., Lv, H., Liu, B., Hao, M., Taylor, H. S., Zhang, X., Li, D., & Huang, Y. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101828 · Cited by 23
Recombinant adeno-associated virus vectors in the treatment of rare diseases
Hastie, E. L., & Samulski, R. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1039511 · Cited by 22
Adeno‐Associated Virus Vector–Based Gene Therapy for Monogenetic Metabolic Diseases of the Liver
Junge, N., Mingozzi, F., Ott, M., & Baumann, U. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000703 · Cited by 21
Self-citationMonahan, P. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.33 · Cited by 22
Genome engineering tools for building cellular models of disease
Lin, J. J., & Musunuru, K. (2016) · FEBS Journal · doi:10.1111/febs.13763 · Cited by 23
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
Fuchs, S. P., Martinez-Navío, J. M., Gao, G., & Desrosiers, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158009 · Cited by 22
Immunomodulatory, liver depot gene therapy for Pompe disease
Bond, J. E., Kishnani, P. S., & Koeberl, D. D. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.011 · Cited by 22
Bioanalysis of Adeno-Associated Virus Gene Therapy Therapeutics: Regulatory Expectations
Gorovits, B., Marshall, J.-C. A., Smith, J., Whiteley, L. O., & Neubert, H. (2019) · Bioanalysis · doi:10.4155/bio-2019-0135 · Cited by 21
Methods for in vitro CRISPR/CasRx-Mediated RNA Editing
Chuang, Y.-F., Wang, P.-Y., Kumar, S., Lama, S., Lin, F.-L., & Liu, G.-S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.667879 · Cited by 21
Ling, C., Li, B., Ma, W., & Srivastava, A. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.054 · Cited by 22
Sitaraman, S., Alysandratos, K., Wambach, J., & Limberis, M. P. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.130 · Cited by 22
Chen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
Chowdary, P., Duran-Jimenez, B., Batty, P. A., Lowe, G., Jones, A., Pollard, D., Boyce, S., Motwani, J., Amirloo, B., Musgrave, K. M., et al. (2024) · Haemophilia · doi:10.1111/hae.15125 · Cited by 25
Self-citationOptimizing hereditary angioedema management through tailored treatment approaches
Nasr, I., Manson, A. L., Wahshi, H. A. A., & Longhurst, H. J. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1100963 · Cited by 21
Santagostino, E., Young, G. A., Carcao, M. D., Mannucci, P. M., Halimeh, S., & Austin, S. K. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1419862 · Cited by 20
French, R. A., Samelson‐Jones, B. J., Niemeyer, G. P., Lothrop, C. D., Merricks, E. P., Nichols, T. C., & Arruda, V. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015313 · Cited by 21
Mahlangu, J. N. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718802606 · Cited by 21
Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine
Minno, G. D., & Tremoli, E. (2017) · Haematologica · doi:10.3324/haematol.2016.156000 · Cited by 21
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 22
Kotterman, M., Beliakoff, G., Croze, R., Vazin, T., Schmitt, C., Szymanski, P., Leong, M., Quezada, M., Holt, J., Barglow, K., et al. (2021) · doi:10.1101/2021.06.24.449775 · Cited by 20
New and improved AAVenues: current status of hemophilia B gene therapy
Brimble, M. A., Reiss, U. M., Nathwani, A. C., & Davidoff, A. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1106475 · Cited by 20
Self-citationMietzsch, M., & Agbandje‐McKenna, M. (2017) · Annual Review of Virology · doi:10.1146/annurev-vi-04-071217-100011 · Cited by 20
Shi, X., Aronson, S. J., ten Bloemendaal, L., Duijst, S., Bakker, R. S., de Waart, D. R., Bortolussi, G., Collaud, F., Elferink, R. P. J. O., Muro, A. F., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.016 · Cited by 20
Self-citationThe intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
Disease burden and management of Crigler‐Najjar syndrome: Report of a world registry
Aronson, S. J., Junge, N., Trabelsi, M., Kelmemi, W., Hubert, A., Brigatti, K. W., Fox, M. D., de Knegt, R. J., Escher, J. C., Ginocchio, V. M., et al. (2022) · Liver International · doi:10.1111/liv.15239 · Cited by 20
Self-citationRestoring Ciliary Function: Gene Therapeutics for Primary Ciliary Dyskinesia
Keiser, N. W., Cant, E., Sitaraman, S., Shoemark, A., & Limberis, M. P. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.102 · Cited by 21
Doshi, B. S., Samelson‐Jones, B. J., Nichols, T. C., Merricks, E. P., Siner, J. I., French, R. A., Lee, B., Arruda, V. R., & Callan, M. B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101205 · Cited by 20
Mesenchymal stem cell treatment for hemophilia: a review of current knowledge
Sokal, E. M., Lombard, C. A., & Mazza, G. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12933 · Cited by 20
Hardet, R., Chevalier, B., Dupaty, L., Naïmi, Y., Riou, G., Drouot, L., Jean, L., Salvetti, A., Boyer, O., & Adriouch, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.146 · Cited by 26
Ultrasound-targeted hepatic delivery of factor IX in hemophiliac mice
Anderson, C. D., Moisyadi, S., Avelar, A., Walton, C. B., & Shohet, R. V. (2016) · Gene Therapy · doi:10.1038/gt.2016.23 · Cited by 20
Nguyen, T. H., & Anegón, I. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606325 · Cited by 20
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
Gardner, M. R., & Farzan, M. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000367 · Cited by 21
Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing
Epstein, B. E., & Schaffer, D. V. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_2 · Cited by 20
Advancement in the treatment of haemophilia
Bhardwaj, R., Rath, G., & Goyal, A. K. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.06.084 · Cited by 20
Li, Y., Li, J., Liu, Y., Shi, Z., Liu, H., Wei, Y., & Yang, L. (2019) · Gene Therapy · doi:10.1038/s41434-019-0081-8 · Cited by 21
Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A
Mannucci, P. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1723547 · Cited by 21
Rathbone, T., Ates, I., Fernando, L. P., Addlestone, E., Lee, C. M., Richards, V. P., & Cottle, R. N. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0134 · Cited by 23
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
Khayat, C. D. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s84597 · Cited by 20
Preclinical models to assess the immunogenicity of AAV vectors
Ertl, H. C. J. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.11.006 · Cited by 20
Palaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.004 · Cited by 19
Inhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
Ozelo, M. C., Mason, J. A., Dunn, A. L., Villaça, P. R., Shen, M., Agarwal, S., Imtiaz, U., Liu, H., & Robinson, T. M. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.12.038 · Cited by 19
Gene Therapy Cargoes Based on Viral Vector Delivery
Lundstrom, K. H. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220921112753 · Cited by 19
In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations
Psatha, N., Paschoudi, K., Παπαδοπούλου, Α., & Yannaki, E. (2022) · Genes · doi:10.3390/genes13122222 · Cited by 24
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 19
Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice
Leal, A. F., Çelik, B., Nidhi, F., Khan, S. A., Tomatsu, S., & Alméciga-Díaz, C. J. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101153 · Cited by 23
Sekayan, T., Simmons, D. H., & von Drygalski, A. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2282138 · Cited by 19
Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy
MUÑOZ, S. A., Bertolin, J., Jiménez, V., Jaén, M. L., García, M., Pujol, A., Vilà, L., Sacristan, V., Barbon, E., Ronzitti, G., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101899 · Cited by 20
Self-citationEvaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, D. M., Nichols, T. C., Merricks, E. P., Palaschak, B., Zolotukhin, I., Marsic, D., Zolotukhin, S., Srivastava, A., & Herzog, R. W. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1200-1 · Cited by 19
Rothwell, W. T., Bell, P. L., Richman, L. K., Limberis, M. P., Tretiakova, A. P., Li, M., & Wilson, J. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0363 · Cited by 19
Hoshino, Y., Nishide, K., Nagoshi, N., Shibata, S., Moritoki, N., Kojima, K., Tsuji, O., Matsumoto, M., Kohyama, J., Nakamura, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46069-z · Cited by 20
Development of Gene Therapy Vectors: Remaining Challenges
Gupta, V., Lourenço, S. P., & Hidalgo, I. J. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.11.035 · Cited by 19
Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target
Ankrom, W., Wood, H. B., Xu, J., Geissler, W. M., Bateman, T. D., Chatterjee, M. S., Feng, K., Metzger, J. M., Strapps, W. R., Tadin‐Strapps, M., et al. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.207 · Cited by 19
The CD8 T‐cell response during tolerance induction in liver transplantation
Wong, Y. C., McCaughan, G. W., Bowen, D. G., & Bertolino, P. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.53 · Cited by 19
Roy‐Chowdhury, J., & Schilsky, M. L. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.017 · Cited by 19
CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A
Luo, S., Li, Z., Dai, X., Zhang, R., Liang, Z., Li, W., Zeng, M., Su, J., Wang, J., Liang, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672564 · Cited by 19
Chai, Z., Zhang, X., Dobbins, A. L., Samulski, R. J., Merricks, E. P., Nichols, T. C., & Li, C. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.083 · Cited by 18
Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy
Shoti, J., Qing, K., Keeler, G. D., Duan, D., Byrne, B. J., & Srivastava, A. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101147 · Cited by 19
Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases
Sussman, C., Liberatore, R. A., & Drozdz, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040535 · Cited by 19
Genetic Targeting of the Albumin Locus to Treat Hemophilia
Davidoff, A. M., & Nathwani, A. C. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1600347 · Cited by 19
Self-citationViral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 19
Gan, S. U., Fu, Z., Sia, K. C., Kon, O. L., Calne, R., & Lee, K. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3067 · Cited by 18
Ragni, M. V., & George, L. A. (2019) · Haemophilia · doi:10.1111/hae.13717 · Cited by 18
Immunotherapy perspectives in the new era of B-cell editing
Ueda, N., Cahen, M., Danger, Y., Moreaux, J., Sirac, C., & Cogné, M. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003792 · Cited by 19
Aradom, E., & Gomez, K. (2021) · The Journal of Haemophilia Practice · doi:10.17225/jhp00174 · Cited by 18
Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE
Parés, M., Fornaguera, C., Vila‐Julià, F., Oh, S., Fan, S. H. Y., Tam, Y. K., Comes, N., Vidal, F., Martí, R., Borrós, S., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.152 · Cited by 18
Frentsch, M., Japp, A. S., Dingeldey, M., Matzmohr, N., Thiel, A., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14757 · Cited by 17
Advances in viral vector-based delivery systems for gene therapy: a comprehensive review
Singh, K., Jain, D., Sethi, P., Gupta, J. K., Dubey, A., Noman, A. A., lal, S., Sharma, P., & Abdallah, E. M. (2025) · 3 Biotech · doi:10.1007/s13205-025-04366-7 · Cited by 21
Kasatkina, L. A., Ma, C., Sheng, H., Lowerison, M. R., Menozzi, L., Baloban, M., Tang, Y., Xu, Y., Humayun, L. L., Vu, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61532-4 · Cited by 17
Factor IX(a) inhibitors: an updated patent review (2003-present)
Afosah, D. K., Ofori, E., Mottamal, M., & Al‐Horani, R. A. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2026926 · Cited by 17
Astermark, J., Blatný, J., Königs, C., Hermans, C. R. J. R., Jiménez‐Yuste, V., & Hart, D. P. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231165857 · Cited by 18
Engineered nanoparticles promote cardiac tropism of AAV vectors
Switala, L. E., Di, L., Gao, H., Asase, C., Klos, M., Palanivel, R., Fedyukina, D. V., & Maiseyeu, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02485-6 · Cited by 18
Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
Miao, C. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0105-1 · Cited by 17
Greig, J. A., Nordin, J. M. L., Bote, E., Makaron, L., Garnett, M. E., Kattenhorn, L. M., Bell, P. L., Goode, T. L., & Wilson, J. M. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.79 · Cited by 17
Wu, L., Xie, J., Tan, L., Mai, Z., Wang, L., Wang, X., & Chen, T. (2017) · Royal Society Open Science · doi:10.1098/rsos.170822 · Cited by 18
Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques
Greig, J. A., Nordin, J. M. L., White, J. W., Wang, Q., Bote, E., Goode, T. L., Calcedo, R., Wadsworth, S. C., Wang, L., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.080 · Cited by 17
Tolerance induction in hemophilia: innovation and accomplishments
Sherman, A., Biswas, M., & Herzog, R. W. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000446 · Cited by 17
Katz, M. G., Gubara, S. M., Hadas, Y., Weber, T., Kumar, A., Eliyahu, E., Bridges, C. R., & Fargnoli, A. S. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.08.089 · Cited by 17
Gene and Cell Therapy for Cardiac Arrhythmias
Ravindran, D., Kok, C., Farraha, M., Selvakumar, D., Clayton, Z. E., Kumar, S., Chong, J. J. H., & Kizana, E. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.09.001 · Cited by 17
Rghei, A. D., Stevens, B. A. Y., Thomas, S. P., Yates, J. G. E., McLeod, B. M., Karimi, K., Susta, L., Bridle, B. W., & Wootton, S. K. (2021) · Journal of Visualized Experiments · doi:10.3791/62727 · Cited by 16
Elkouby, L., Armour, S. M., Toso, R., DiPietro, M. A., Davidson, R. J., Nguyen, G. N., Willet, M., Kutza, S., Silverberg, J., Frick, J. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.005 · Cited by 18
Self-citationProgress toward improved therapies for inborn errors of metabolism
Ginocchio, V. M., & Brunetti‐Pierri, N. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv418 · Cited by 19
Qizhao, W., Firrman, J., Wu, Z., Pokiniewski, K. A., Valencia, C. A., Wang, H., Wei, H., Zhuang, Z., Liu, L., Wunder, S. L., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.055 · Cited by 17
Early clinical data raise the bar for hemophilia gene therapies
Dolgin, E. (2016) · Nature Biotechnology · doi:10.1038/nbt1016-999 · Cited by 16
Gene Therapy: Paving New Roads in the Treatment of Hemophilia
Yamaguti-Hayakawa, G. G., & Ozelo, M. C. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1688445 · Cited by 16
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 17
Hughes, M. P., Nelvagal, H. R., Coombe-Tennant, O., Smith, D., Smith, C., Massaro, G., Poupon-Bejuit, L., Platt, F. M., & Rahim, A. A. (2023) · Cells · doi:10.3390/cells12121619 · Cited by 16
CRISPR/Cas9 as a Mutagenic Factor
Shumega, A. R., Pavlov, Y. I., Chirinskaite, A. V., Rubel, A. A., Inge-Vechtomov, S. G., & Stepchenkova, E. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020823 · Cited by 18
Current and future prospects for hemophilia gene therapy
Ward, P., & Walsh, C. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1182859 · Cited by 16
Recent advances in hemophilia B therapy
Horava, S. D., & Peppas, N. A. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0365-8 · Cited by 16
Sun, J., Hua, B., Chen, X., Samulski, R. J., & Li, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.016 · Cited by 16
Roadmap for an early gene therapy for cystic fibrosis airway disease
Carlon, M. S., Vidović, D., & Birket, S. E. (2017) · Prenatal Diagnosis · doi:10.1002/pd.5164 · Cited by 16
Leggiero, E., Labruna, G., Iaffaldano, L., Lombardo, B., Greco, A., Fiorenza, D., Gramanzini, M., Montanaro, D., Baldi, A., Cerullo, V., et al. (2019) · Gene Therapy · doi:10.1038/s41434-019-0061-z · Cited by 15
Morelli, K. H., Hatton, C. L., Harper, S. Q., & Burgess, R. W. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146683 · Cited by 16
Watano, R., Ohmori, T., Hishikawa, S., Sakata, A., & Mizukami, H. (2020) · Gene Therapy · doi:10.1038/s41434-020-0125-0 · Cited by 16
Sharma, A., Mathew, M. E., Sriganesh, V., & Reiss, U. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub3 · Cited by 15
Self-citationFerri, L., Covello, G., Caciotti, A., Guerrini, R., Denti, M. A., & Morrone, A. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.88 · Cited by 16
Ameratunga, R., Bartlett, A. S., McCall, J. L., Steele, R. H., Woon, S., & Katelaris, C. H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00547 · Cited by 16
Evolving Complexity in Hemophilia Management
Croteau, S. E. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.004 · Cited by 17
AAV-Mediated Gene Delivery to the Mouse Liver
Cunningham, S. C., & Alexander, I. E. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9065-8_12 · Cited by 17
Metadata
- Authors
- Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., Pie, J., Rangarajan, S., Bevan, D., Recht, M., Shen, Y.-M., Halka, K. G., Basner-Tschakarjan, E., Mingozzi, F., High, K. A., Allay, J., Kay, M. A., Ng, C. Y. C., Zhou, J., Cancio, M., Morton, C. L., Gray, J. T., Srivastava, D., Nienhuis, A. W., & Davidoff, A. M.
- Affiliations
- NHS Blood and Transplant (GB)
- Royal Free London NHS Foundation Trust (GB)
- University College London (GB)
- St Thomas' Hospital (GB)
- Oregon Health & Science University (US)
- The University of Texas Southwestern Medical Center (US)
- Children's Hospital of Philadelphia (US)
- St. Jude Children's Research Hospital (US)
- Stanford Medicine (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1994-2004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4278802
- OpenAlex
- W1969271703
- Cited by
- 1,273
- References
- 17
- Citations by year
- 2026: 44 · 2025: 64 · 2024: 80 · 2023: 99 · 2022: 118 · 2021: 119 · 2020: 133 · 2019: 125 · 2018: 139 · 2017: 144 · 2016: 108 · 2015: 92 · 2014: 2
- FWCI
- 81.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Assisi Foundation of Memphis
- NHS Blood and Transplant
- American Lebanese Syrian Associated Charities
- National Institute for Health and Care Research (RP-PG-0310-1001, NF-SI-0513-10071)
- University College London
- University College London Hospitals NHS Foundation Trust
- Medical Research Council
- National Heart, Lung, and Blood Institute (HL094396, R01HL094396, R01HL073838, R01HL064274)
- National Cancer Institute (P30CA021765)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, AAV8 vector, self-complementary AAV, dose-response relationship, long-term safety, late toxicity, alanine aminotransferase elevation, bleeding events
- MeSH terms
- Dependovirus, Adult, Alanine Transaminase, Hemophilia B, Factor IX, Follow-Up Studies, Genetic Vectors, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Gene Expression, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
